ELEVANCE HEALTH INC

Elevance Health declares a $1.72 per‑share dividend, yielding 1.68%, showing financial strength amid rising Treasury yields and offering modest income for investors.

Elevance Health’s senior executives sold vested RSU shares to cover taxes, keeping ownership and governance steady – a routine move reflecting standard industry practice.

Elevance Health’s Form 4 filings show routine executive RSU tax‑withholding sales at market price, confirming transparent governance and compliance.

Elevance Health teams with HABRI and Airvet to turn pet‑ownership into an employer‑level wellness KPI, unlocking data‑driven benefits and new revenue streams.

ASX 200 dips as RBA rate‑hike expectations rise; Ramsay Health leads the healthcare sector, while ELEVANCE HEALTH remains flat but poised for value‑based growth amid shifting reimbursement models.

SEC Form 4 reveals ELEVANCE HEALTH’s share gift to a trust, reducing owner influence while keeping board continuity—and highlights ELEV‑01’s promising 42% response rate.

AN2 Therapeutics’ insider gift to a trust signals possible restructuring and future funding plans, while Ashok Leyland’s 12 % revenue jump and premium‑EV push reveal a strategic pivot toward higher‑margin, sustainable commercial vehicles.

Explore Maruti Suzuki’s 2025‑26 BRSR – ESG goals, solar expansion, electrification, gender diversity, and assurance details that set new automotive sustainability standards.

Elevance Health’s latest quarterly earnings show modest revenue growth, improved margins, and a cautious yet optimistic outlook, boosting investor confidence.

Elevance Health directors receive instant‑vested shares in a new compensation plan, spotlighting short‑term incentives, governance risks and future strategy in the health‑services market.